Stuart M. Grant Acquires 100,000 Shares of Eyenovia, Inc. (NASDAQ:EYEN) Stock

Eyenovia, Inc. (NASDAQ:EYEN – Get Rating) major shareholder Stuart M. Grant bought 100,000 shares of the stock in a transaction dated Tuesday, June 21st. The stock was bought at an average price of $1.65 per share, with a total value of $165,000.00. Following the acquisition, the insider now owns 5,084,998 shares in the company, valued at approximately $8,390,246.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

NASDAQ:EYEN traded up $0.09 during trading hours on Thursday, reaching $1.80. 2,952 shares of the company’s stock were exchanged, compared to its average volume of 108,347. The firm has a market capitalization of $60.43 million, a price-to-earnings ratio of -3.17 and a beta of 2.08. The company has a 50-day moving average of $2.21 and a 200 day moving average of $2.89. Eyenovia, Inc. has a 1-year low of $1.61 and a 1-year high of $6.63.

Eyenovia (NASDAQ:EYEN – Get Rating) last announced its quarterly earnings data on Monday, March 28th. The company reported $0.10 EPS for the quarter. The firm had revenue of $10.00 million for the quarter. During the same period in the prior year, the firm posted ($0.17) EPS. Equities research analysts forecast that Eyenovia, Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp increased its holdings in Eyenovia by 9.3% during the 1st quarter. State Street Corp now owns 61,617 shares of the company’s stock valued at $188,000 after acquiring an additional 5,217 shares in the last quarter. Hexagon Capital Partners LLC purchased a new position in Eyenovia during the 1st quarter valued at about $30,000. Renaissance Technologies LLC increased its holdings in Eyenovia by 32.6% during the 3rd quarter. Renaissance Technologies LLC now owns 197,800 shares of the company’s stock valued at $969,000 after acquiring an additional 48,652 shares in the last quarter. Finally, AMH Equity Ltd purchased a new position in Eyenovia during the 4th quarter valued at about $400,000. Institutional investors and hedge funds own 23.36% of the company’s stock.

Eyenovia Company Profile (Get Rating)

Eyenovia, Inc, a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.

See Also